Getting a therapeutic peptide into the cytosol of a neuron.

Two patented, complementary technologies: a VHH-based intracellular vectorization platform, and a neuroprotective and neuroregenerative peptide pharmacophore derived from a rabies virus glycoprotein motif. Both arising from academic research carried out at Institut Pasteur.

injury axonal regrowth neuronal survival
The assets

One delivery platform, one pharmacophore

Two international patent applications, both published on 26 December 2025 and co-owned with Institut Pasteur. They were filed as a deliberate architecture, not as two independent programmes.

WO 2025/262307 A2

VHH_NPX vectorization platform

Platform patent

An unusual single-domain antibody, engineered to cross two barriers that stop most therapeutics: the blood–brain barrier, and then the plasma membrane of the neuron itself — releasing its cargo into the cytosol rather than trapping it in the endosomal compartment.

  • Claims the VHH_NPX scaffold, the VHH–NVshort complexes, compositions and uses
  • Direct cytosolic access, reduced endosomal degradation
  • Designed to cross the blood–brain barrier, opening a systemic route to CNS targets
  • Demonstrated with peptide cargo and with oligonucleotides (PMO / ASO)
  • Broad claim scope — the platform and lead-product patent
WO 2025/262278 A1

NVshort neuroprotective peptide

Composition of matter

A truncated pharmacophore that retains the activity of the parent 42-amino-acid sequence, in a form short enough to be manufactured and fused.

  • Composition of matter on the pharmacophore itself
  • Truncation to 11–15 amino acids with no measurable loss of activity
  • Applications in optic nerve injury
  • Distinguishes over the company's own prior art (NVlong, 42 aa)
Why this pairing matters. The two filings cover both halves of the same problem: getting a drug inside the neuron itself, with the highest achievable efficiency. That remains one of the field's genuinely unmet problems.
Science

A lethal virus that keeps neurons alive

Rabies is among the most lethal pathogens known to medicine — once symptoms appear, survival is almost unheard of. Yet a pathologist examining the brain of a victim finds strikingly little destruction. The neurons are still alive.

The virus has evolved a robust mechanism that forces neurons to survive. It enters at a peripheral wound and reaches the brain by travelling along the nervous system itself, a journey that only succeeds if the neurons it passes through stay alive. So it does the opposite of what its reputation suggests: it actively prevents the cells it infects from dying.

Work led by Monique Lafon — co-founder and Chief Scientific Officer of Neurophoenix — in her laboratory at Institut Pasteur traced that ability to a short motif at the C-terminus of the viral glycoprotein, and to its interaction with MAST2, a host scaffolding protein. The premise of Neurophoenix is to keep the motif and leave the virus behind.

NVshort a PDZ-binding motif (PBM) that binds MAST2-PDZ PTEN–MAST2 that single interaction is inactivated PI3K / Akt / mTOR survival pathway of the adult neuron is reactivated Neuron survives and regrows its axon
Delivery

The bottleneck is not entry — it is the endosomal route

The problem

Cell-penetrating peptides such as TAT enter cells efficiently — but they enter through the endosomal pathway. The cargo is taken up into a vesicle, and the great majority of it is degraded there before ever reaching the cytosol.

The cost is not only lost activity. Compensating for what is destroyed means raising the dose, and raising the dose raises toxicity. A delivery route that avoids the endosome therefore improves the therapeutic window, not just the potency.

The approach

VHH_NPX is designed for direct cytosolic access, bypassing endocytic uptake rather than trying to escape from it afterwards. In head-to-head comparisons against TAT, the platform showed a 7-fold advantage in vitro and 4.7-fold in vivo.

Conventional CPP (e.g. TAT) membrane endosome degraded before reaching target VHH_NPX membrane direct cytosolic access target engaged 7× in vitro · 4.7× in vivo vs TAT
Schematic representation, not to scale. Fold-differences are the company's own head-to-head measurements.

The lead compound. NPX461 fuses the VHH_NPX domain to the NVshort peptide in a single protein of roughly 15 kDa — small enough to distribute through tissue, large enough to be produced by recombinant expression in bacteria or in mammalian cells. Its antigen-binding loop has been deliberately deactivated, so the antibody scaffold works purely as a vehicle and carries no residual target specificity of its own. It is soluble above 50 mg/mL at physiological pH, and has been measured as high as 130 mg/mL, which leaves ample room for high-concentration formulation; it carries no His-tag.

The same vehicle has been shown to deliver two very different payloads — a therapeutic peptide and an antisense oligonucleotide. That is what makes the platform relevant beyond this single programme.

Development status

Preclinical, with in vivo proof of concept in the optic nerve

In a rodent optic nerve crush model, the vectorized fusion protein protected retinal ganglion cells and produced 250–550 µm of axonal regeneration. Activity has been observed in several human cell types.

Completed

  • Murine efficacy data, optic nerve crush model
  • In vitro and in vivo head-to-head comparisons against TAT
  • Characterisation of the NPX461 fusion protein
  • Both patent applications filed and published

To be completed

  • GLP and regulatory toxicology
  • Non-rodent species
  • GMP manufacturing
  • Regulatory filing (IND / CTA)
Intellectual property

Two PCT applications, co-owned with Institut Pasteur

ApplicationSubjectPublication
WO 2025/262307 A2 VHH suitable to vectorize molecules intracellularly — platform and lead-product claims 26 December 2025
WO 2025/262278 A1 A neurovita short interfering peptide — composition of matter 26 December 2025

Both applications claim priority from 21 June 2024 and are held in equal co-ownership (50/50) with Institut Pasteur. Full texts are available on WIPO Patentscope.

Team

A small team, with the founding science in-house

Neurophoenix operates as a focused team. Its two co-founders lead the company, and the scientist behind the original discovery remains its Chief Scientific Officer. The underlying work was carried out in the laboratory of Monique Lafon at Institut Pasteur, which remains co-owner of both patent families.

Monique Lafon

Monique Lafon

Co-founder & Chief Scientific Officer

Neurovirologist, Institut Pasteur. Established the link between the rabies virus glycoprotein motif, MAST2 and neuronal survival that underpins the NVshort pharmacophore.

Pascal Voisin

Pascal Voisin

Co-founder & Executive Chairman

Responsible for the company's corporate development, intellectual property strategy and partnering.

Supported since inception by

Institut Pasteur Bpifrance ANR i-Lab Agoranov Région Île-de-France Medicen France Biotech
Contact

Partnering and corporate enquiries